All Comparisons/Aiforia vs Proscia

VNDRIQ — Vendor Comparison

Aiforia vs Proscia

Side-by-side comparison of BAA status, PHI exposure, AI training risk, HIPAA suitability, and VNDRIQ governance scores.

Aiforia53
Proscia71

Aiforia

Digital Pathology AI

Last verified: September 30, 2026

Proscia

Digital Pathology AI

Last verified: September 16, 2026

VNDRIQ Scores

53

Overall

Privacy Score62
Governance Score33
Healthcare Readiness50
AI Risk Score65

71

Overall

Privacy Score61
Governance Score71
Healthcare Readiness63
AI Risk Score90

Approval Tier

Restricted / Review Required
Approved With Restrictions

BAA Status

Verify Directly
Available for clinical customers; the platform aligns with HIPAA and GDPR privacy standards.

PHI Exposure Risk

Medium
Medium

AI Training Risk

Medium
Low

HIPAA Risk Level

Medium
Medium

Review Frequency

—

Quarterly

Recommended Use

—

Primary pathology diagnosis using whole slide imaging (WSI) in clinical laboratories, specifically for FFPE tissue specimens.

Restrictions

—

Concentriq AP-Dx is not intended for use with frozen sections, cytology, or non-FFPE hematopathology specimens. Native AI features and interoperable AI applications are currently for Research Use Only (RUO) in many contexts.

Executive Summary

Aiforia

Digital Pathology AI

Aiforia is classified as Restricted / Review Required with a BAA status of Verify Directly. PHI exposure is rated Medium and AI training risk is Medium.

62

Privacy

33

Governance

50

Healthcare

65

AI Risk

Proscia

Digital Pathology AI

Proscia is classified as Approved With Restrictions with a BAA status of Available for clinical customers; the platform aligns with HIPAA and GDPR privacy standards.. PHI exposure is rated Medium and AI training risk is Low. Primary pathology diagnosis using whole slide imaging (WSI) in clinical laboratories, specifically for FFPE tissue specimens.

61

Privacy

71

Governance

63

Healthcare

90

AI Risk

Recommended For

Aiforia

Currently under review — not recommended for active PHI deployment

Proscia

Primary pathology diagnosis using whole slide imaging (WSI) in clinical laboratories, specifically for FFPE tissue specimens.

Organizations with established governance workflows

Multi-location healthcare groups needing standardized vendor status

Governance Considerations

Aiforia

BAA has not been confirmed. Execute BAA before processing PHI.

Proscia

Quarterly reviews are required — establish internal review cadence.

Restrictions noted: Concentriq AP-Dx is not intended for use with frozen sections, cytology, or non-FFPE hematopathology specimens. Native AI features and interoperable AI applications are currently for Research Use Only (RUO) in many contexts.

Questions to Ask Before Approval

01

Has the vendor executed a Business Associate Agreement (BAA) with your organization?

02

Does the vendor use customer data to train AI models? Can you opt out?

03

Where is PHI stored, processed, and transmitted?

04

What data retention and deletion policies apply to your PHI?

05

Has the vendor undergone a third-party HIPAA or SOC 2 audit?

06

What is the vendor's incident response and breach notification process?

07

Does the vendor offer audit logging for PHI access?

08

What subprocessors have access to PHI through this vendor?

Request Vendor Evaluation

Get a structured risk assessment for any vendor.

Request Benchmark Report

Compare vendors across your full stack.

Book Governance Assessment

Talk to a VNDRIQ governance specialist.